NASDAQ •
Healthcare •
Biotechnology •
Quote as of 05/15/2026
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization1,331.01 mln
Float39.86 mln
Earnings Date08/12/2026
Piotroski F-Score
1
/ 9
Very weak
1-Year Forecast
26.77
Exceptional upside
Relative Strength
84
/ 100
Strongly outperforming
Debt / Equity
0.40
Low leverage
ROE
-79.91
Deeply negative
Dividend Yield
0.00%
No dividend
Business Description
MoonLake Immunotherapeutics is a Swiss biotech company working to bring new treatments to patients suffering from inflammatory skin and joint conditions. Its primary focus is Sonelokimab, a next-generation molecule designed to block key proteins that drive inflammation, targeting conditions such as psoriasis, psoriatic arthritis, and related disorders. Founded in 2021 and based in Zug, Switzerland, the company is currently running clinical trials to advance this therapy toward approval.
